Esketamine Nasal Spray: Efficacy and Safety in TRD

Esketamine Nasal Spray: A Promising Treatment for TRD

Esketamine nasal spray offers a rapid-acting treatment option for individuals with treatment-resistant depression (TRD), a condition where traditional therapies fail to provide relief. This systematic review, published on June 30, 2026, integrates clinical trial data and real-world evidence to assess esketamine's efficacy and safety. The review highlights esketamine's ability to reduce depressive symptoms more effectively than placebo and other treatments, such as quetiapine, with many patients experiencing improvement within days.

Mechanism and Context: How Esketamine Works

Esketamine functions by targeting the N-methyl-D-aspartate (NMDA) receptor in the brain, which is distinct from the mechanisms of traditional antidepressants. This unique action allows for rapid symptom relief, with effects lasting weeks to months after treatment cessation. The review underscores the importance of esketamine as a standalone therapy for TRD, providing an alternative for patients unresponsive to existing medications.

Policy and Research Implications

The findings from this review have significant implications for both clinical practice and future research. Esketamine's rapid efficacy and manageable safety profile suggest it could be an important addition to the treatment arsenal for TRD. However, the review also calls for further investigation into optimal dosing strategies and long-term effects, as current data beyond 12 months is limited. Ongoing phase 3 trials are expected to provide more comprehensive insights into these areas.

Risks and Unknowns: Safety and Long-Term Effects

While esketamine has shown a promising safety profile, with most side effects being mild to moderate and resolving within two hours, there are still concerns about its long-term safety and efficacy. The review notes the need for larger sample sizes and extended follow-up periods in future studies to better understand potential risks and benefits over time. Additionally, the potential for misuse or dependency, although not highlighted in the current review, remains a consideration for clinicians and policymakers.

Looking Forward: The Future of Esketamine in Treating TRD

As research continues, esketamine nasal spray could become a cornerstone treatment for TRD, offering hope to patients who have exhausted other options. The integration of patient feedback into treatment plans, as noted in the review, may enhance personalized care and improve outcomes. Stakeholders in the field should keep a close eye on upcoming trial results to inform best practices and policy decisions.